Erlotinib

Curated

← predicts response to

2 source records aggregated

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

6 source records aggregated

sensitivity

Curated

← predicts response to

EGFR Exon 19 Deletiondeletion

5 source records aggregated

sensitivity

Curated

Lung Non-Small Cell Carcinoma,Malignant Lung Neoplasm

← predicts response to

EGFR Mutationother

4 source records aggregated

sensitivity

Curated

← predicts response to

KRAS Mutationother

3 source records aggregated

resistance

Curated

← predicts response to

EGFR G719

2 source records aggregated

sensitivity

Curated

← predicts response to

2 source records aggregated

resistance

Curated

← predicts response to

EGFR Amplificationamplification

2 source records aggregated

sensitivity

Curated

← predicts response to

KRAS Mutationother

sensitivity

Curated

← predicts response to

GNAS c.393T>CSNV

resistance

Curated

← predicts response to

EGFR Exon 18 Overexpressionexpression

sensitivity

Curated

← predicts response to

EGFR L861

sensitivity

Curated

← predicts response to

PIK3CA Mutationother

resistance

Curated

← predicts response to

EGFR G719SSNV

sensitivity

Curated

← predicts response to

KRAS G12CSNV

resistance

Curated

← predicts response to

PTEN Expressionexpression

sensitivity

Glioblastoma

Curated

← predicts response to

EGFR VIIIdeletion

sensitivity

Glioblastoma

Curated

EGFR Y1092 PHOSPHORYLATION

← predicts response to

sensitivity

Curated

← predicts response to

KRAS G12ASNV

resistance

Curated

← predicts response to

KRAS G12/G13

resistance

Curated

EGFR Rare Exon 18-21 Mutation

← predicts response to

sensitivity

Curated

← predicts response to

KRAS Exon 2 MutationSNV

resistance

Curated

← predicts response to

RAD51 Fusionfusion

3 source records aggregated

sensitivity

Curated

← predicts response to

EGFR E746GSNV

sensitivity

Curated

← predicts response to

ERBB2 Amplificationamplification

resistance

Curated

← predicts response to

EGFR Amplificationamplification

sensitivity

Colon Adenocarcinoma

Curated

← predicts response to

SEPTIN14 Fusionfusion

sensitivity

Colon Adenocarcinoma

Curated

← predicts response to

sensitivity

Curated

← predicts response to

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

MET Amplificationamplification

resistance

Curated

Lung Acinar Adenocarcinoma

← predicts response to

ALK Fusionfusion

resistance

Curated

← predicts response to

PURB Fusionfusion

sensitivity

Curated

Pancreatic Adenocarcinoma

← predicts response to

EGFR L747_P753delinsSdeletion

sensitivity

Curated

← predicts response to

EGFR P772_H773insYNPinsertion

resistance

Curated

← predicts response to

EGFR L747_S752delinsQinsertion

sensitivity

Curated

← predicts response to

EGFR H773_V774insNPHinsertion

resistance

Curated

← predicts response to

EGFR G719DSNV

sensitivity

Curated

Minimally Invasive Lung Adenocarcinoma

← predicts response to

EGFR E746_A750deldeletion

sensitivity

Curated

← predicts response to

EGFR V769_D770insASVinsertion

sensitivity

Curated

← predicts response to

EGFR K757RSNV

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

EGFR D761YSNV

resistance

Curated

← predicts response to

EGFR S768ISNV

sensitivity

Curated

← predicts response to

sensitivity

Curated

Lung Squamous Cell Carcinoma

← predicts response to

DDR2 S768RSNV

sensitivity

Curated

← predicts response to

RAD51 e24::e4fusion

sensitivity

Curated

← predicts response to

EGFR D770delinsGYinsertion

resistance

Curated

← predicts response to

EGFR D770_N771insGLinsertion

resistance

Curated

← predicts response to

EGFR Mutationother

sensitivity

Curated

← predicts response to

resistance

Curated

Head and Neck Squamous Cell Carcinoma

← predicts response to

MAPK1 E322KSNV

sensitivity

Curated

← predicts response to

EGFR Exon 19 Deletiondeletion

sensitivity

Curated

← predicts response to

EGFR A767_V769dupASVinsertion

resistance

Curated

← predicts response to

EGFR Exon 20 Insertioninsertion

resistance

Curated

← predicts response to

EGFR D770_N771insGTinsertion

resistance

Curated

← predicts response to

EGFR S768ISNV

resistance

Curated

← predicts response to

High-Grade Glioma, NOS,Lung Adenocarcinoma,Lung Non-Small Cell Carcinoma+2

10 source records aggregated

sensitivity

Curated

← predicts response to

EGFR L838VSNV

resistance

Curated

← predicts response to

EGFR G598VSNV

sensitivity

Curated

← predicts response to

BRAF V600ESNV

sensitivity

Curated

← predicts response to

EGFR Y801HSNV

sensitivity

Curated

← predicts response to

EGFR C797YSNV

sensitivity

Curated

← predicts response to

EGFR T785ASNV

sensitivity

Curated

← predicts response to

EGFR E734QSNV

sensitivity

Curated

← predicts response to

EGFR W731LSNV

sensitivity

Curated

← predicts response to

EGFR VIIIdeletion

sensitivity

Curated

← predicts response to

EGFR E868GSNV

sensitivity

Curated

← predicts response to

EGFR L861QSNV

sensitivity

Curated

← predicts response to

EGFR R831HSNV

sensitivity

Curated

← predicts response to

EGFR A289VSNV

sensitivity

Curated

← predicts response to

EGFR T263PSNV

sensitivity

Curated

← predicts response to

EGFR R108KSNV

sensitivity

Curated

← predicts response to

resistance

Curated

← predicts response to

EGFR Y764_V765insHHinsertion

resistance

Curated

← predicts response to

EGFR M766_A767insAIinsertion

resistance

Curated

← predicts response to

EGFR A763_Y764insFQEAinsertion

sensitivity

Curated

← predicts response to

EGFR N826SSNV

resistance

Curated

← predicts response to

EGFR A864TSNV

sensitivity

Curated

← predicts response to

EGFR R776CSNV

sensitivity

Curated

← predicts response to

EGFR H773_V774insHinsertion

resistance

Curated

← predicts response to

EGFR D770_N771insSVDinsertion

resistance

Curated

← predicts response to

EGFR L747_P753delinsSdeletion

sensitivity

Curated

← predicts response to

EGFR V742ASNV

sensitivity

Curated

← predicts response to

EGFR G719SSNV

sensitivity

Curated

Erlotinib targets …TARGETS1 of 1
→ targets	EGFR	—	INHIBITOR	—	1	Curated	chembl	graph →

Erlotinib targets …TARGETS1 of 1

→ targets

EGFR

—

INHIBITOR

—

Curated

chembl

Erlotinib investigated for …INVESTIGATED_FOR15 of 78show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype 4 source records aggregated	supports	A	Lung Non-Small Cell Carcinoma	4	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 26 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	26	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype 5 source records aggregated	supports	B	Lung Adenocarcinoma	5	Curated	civic	graph →
→ investigated for	Glioblastomasubtype 2 source records aggregated	supports	B	Glioblastoma	2	Curated	civic	graph →
→ investigated for	Malignant Lung Neoplasmcancer	supports	B	Malignant Lung Neoplasm	1	Curated	civic	graph →
→ investigated for	Malignant Colorectal Neoplasmsubtype	supports	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
→ investigated for	Malignant Pancreatic Neoplasmcancer	supports	B	Malignant Pancreatic Neoplasm	1	Curated	civic	graph →
→ investigated for	Pancreatic Neoplasmsubtype	unknown	4	Pancreatic Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Adenocarcinomasubtype 21 source records aggregated	supports	C	Lung Adenocarcinoma	21	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype 8 source records aggregated	supports	C	Lung Non-Small Cell Carcinoma	8	Curated	civic	graph →
→ investigated for	Colon Adenocarcinomasubtype	supports	C	Colon Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	Cholangiocarcinomasubtype	supports	C	Cholangiocarcinoma	1	Curated	civic	graph →
→ investigated for	Lung Acinar Adenocarcinomasubtype	supports	C	Lung Acinar Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	Pancreatic Adenocarcinomasubtype	supports	C	Pancreatic Adenocarcinoma	1	Curated	civic	graph →

Erlotinib investigated for …INVESTIGATED_FOR15 of 78show all (up to 200)

→ investigated for

4 source records aggregated

supports

Curated

→ investigated for

26 source records aggregated

supports

Curated

→ investigated for

Lung Adenocarcinomasubtype

5 source records aggregated

supports

Curated

→ investigated for

Glioblastomasubtype

2 source records aggregated

supports

Glioblastoma

Curated

→ investigated for

Malignant Lung Neoplasmcancer

supports

Malignant Lung Neoplasm

Curated

→ investigated for

Malignant Colorectal Neoplasmsubtype

supports

Curated

→ investigated for

Malignant Pancreatic Neoplasmcancer

supports

Curated

→ investigated for

Pancreatic Neoplasmsubtype

unknown

Pancreatic Neoplasm

Curated

chembl

→ investigated for

unknown

Curated

chembl

→ investigated for

Lung Adenocarcinomasubtype

21 source records aggregated

supports

Curated

→ investigated for

8 source records aggregated

supports

Curated

→ investigated for

Colon Adenocarcinomasubtype

supports

Colon Adenocarcinoma

Curated

→ investigated for

Cholangiocarcinomasubtype

supports

Cholangiocarcinoma

Curated

Lung Acinar Adenocarcinoma

→ investigated for

Lung Acinar Adenocarcinomasubtype

supports

Curated

Pancreatic Adenocarcinoma

→ investigated for

Pancreatic Adenocarcinomasubtype

supports

Curated

Erlotinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 168 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	168	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasmcancer 30 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasmcancer 29 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Squamous Non-Small Cell Carcinoma 25 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 22 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 22 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 15 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasm 10 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinoma 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasm 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Adenocarcinomasubtype 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	4	Observed	clinicaltrials	graph →

Erlotinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 144show all (up to 200)

→ investigated in trials for

168 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

168

Observed

→ investigated in trials for

Malignant Lung Neoplasmcancer

30 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Lung Neoplasm

Observed

→ investigated in trials for

Malignant Pancreatic Neoplasmcancer

29 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Lung Non-Squamous Non-Small Cell Carcinoma

→ investigated in trials for

25 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Squamous Non-Small Cell Carcinoma

Observed

→ investigated in trials for

22 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Solid Neoplasm

22 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Malignant Head and Neck Neoplasm

→ investigated in trials for

15 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Head and Neck Neoplasm

Observed

→ investigated in trials for

Neoplasm

10 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Neoplasm

Observed

Malignant Breast Neoplasm

→ investigated in trials for

9 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Breast Neoplasm

Observed

→ investigated in trials for

Malignant Colorectal Neoplasmsubtype

9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Hepatocellular Carcinoma

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hepatocellular Carcinoma

Observed

→ investigated in trials for

Lung Neoplasm

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Neoplasm

Observed

Pancreatic Adenocarcinoma

→ investigated in trials for

Pancreatic Adenocarcinomasubtype

6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Brain Neoplasm

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Brain Neoplasm

Observed

→ investigated in trials for

Renal Cell Carcinoma

4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Renal Cell Carcinoma

Observed

Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma

Erlotinib studied in …STUDIED_INderived10 of 401show all (up to 200)
→ studied in	NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 401 trials list this drug (13 active)	—	—	Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · 401 trials list this drug (13 active)	—	—	Hereditary Leiomyomatosis and Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Carcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04449874Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation · 401 trials list this drug (13 active)	—	—	Solid Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01562028Phase 2 · completed BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) · 401 trials list this drug (13 active)	—	—	Malignant Lung Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01652469Phase 3 · completed Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. · 401 trials list this drug (13 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · 401 trials list this drug (13 active)	—	—	Cervical Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma,Leiomyosarcoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT00640978Phase 2 · terminated Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer · 401 trials list this drug (13 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00942734Phase 2 · completed Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma · 401 trials list this drug (13 active)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05525858recruiting KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II · 401 trials list this drug (13 active)	—	—	Malignant Neoplasm,Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00304278Phase 2 · completed Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) · 401 trials list this drug (13 active)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →

Erlotinib studied in …STUDIED_INderived10 of 401show all (up to 200)

→ studied in

NCT02194738NA · active not recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 401 trials list this drug (13 active)

—

Observed

Hereditary Leiomyomatosis and Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Carcinoma+1

→ studied in

NCT04981509Phase 2 · recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · 401 trials list this drug (13 active)

—

Observed

Solid Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm

→ studied in

NCT04449874Phase 1 · active not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation · 401 trials list this drug (13 active)

—

Observed

→ studied in

NCT01562028Phase 2 · completed

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) · 401 trials list this drug (13 active)

—

Malignant Lung Neoplasm

Observed

→ studied in

NCT01652469Phase 3 · completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. · 401 trials list this drug (13 active)

—

Observed

Cervical Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma,Leiomyosarcoma+2

→ studied in

NCT05827614Phase 1 · terminated

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · 401 trials list this drug (13 active)

—

Observed

→ studied in

NCT00640978Phase 2 · terminated

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer · 401 trials list this drug (13 active)

—

Observed